CR20210669A - Vectores víricos y uso de los mismos en terapias celulares adoptivas - Google Patents
Vectores víricos y uso de los mismos en terapias celulares adoptivasInfo
- Publication number
- CR20210669A CR20210669A CR20210669A CR20210669A CR20210669A CR 20210669 A CR20210669 A CR 20210669A CR 20210669 A CR20210669 A CR 20210669A CR 20210669 A CR20210669 A CR 20210669A CR 20210669 A CR20210669 A CR 20210669A
- Authority
- CR
- Costa Rica
- Prior art keywords
- viral vectors
- cellular therapy
- adoptive cellular
- dimer
- encoding
- Prior art date
Links
- 238000002659 cell therapy Methods 0.000 title 1
- 239000013603 viral vector Substances 0.000 title 1
- 239000000539 dimer Substances 0.000 abstract 4
- 239000002773 nucleotide Substances 0.000 abstract 4
- 125000003729 nucleotide group Chemical group 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Un vector que contiene una primera secuencia nucleotídica S1, que codifica una proteína Z, una segunda secuencia nucleotídica S2, que codifica una proteína Z2, una tercera secuencia nucleotídica S3, que codifica una proteína Y1, y una cuarta secuencia nucleotídica S4, que codifica una proteína Y2, en que Z1 y Z2 forman un primer dímero e Y1 y Y2 forman un segundo dímero, en que el primer dímero Z1Z2 es diferente del segundo dímero Y1Y2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962853123P | 2019-05-27 | 2019-05-27 | |
PCT/US2020/034639 WO2020243134A1 (en) | 2019-05-27 | 2020-05-27 | Viral vectors and their use in adoptive cellular therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20210669A true CR20210669A (es) | 2022-05-05 |
Family
ID=71094837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20210669A CR20210669A (es) | 2019-05-27 | 2020-05-27 | Vectores víricos y uso de los mismos en terapias celulares adoptivas |
Country Status (19)
Country | Link |
---|---|
US (1) | US11975025B2 (es) |
EP (1) | EP3976805A1 (es) |
JP (1) | JP2022534716A (es) |
KR (1) | KR20220029584A (es) |
CN (1) | CN113874516A (es) |
AU (1) | AU2020283500A1 (es) |
BR (1) | BR112021023782A2 (es) |
CA (1) | CA3141505A1 (es) |
CL (1) | CL2021003146A1 (es) |
CO (1) | CO2021017650A2 (es) |
CR (1) | CR20210669A (es) |
EA (1) | EA202193139A1 (es) |
IL (1) | IL288403A (es) |
MA (1) | MA56036A (es) |
MX (1) | MX2021014552A (es) |
PE (1) | PE20220164A1 (es) |
SG (1) | SG11202112860PA (es) |
TW (1) | TW202110875A (es) |
WO (1) | WO2020243134A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4032544A3 (en) | 2016-12-08 | 2022-12-21 | Immatics Biotechnologies GmbH | Novel t cell receptors and immune therapy using the same |
MX2021013225A (es) * | 2019-05-01 | 2022-01-06 | Pact Pharma Inc | Composiciones y metodos para el tratamiento del cancer utilizando una terapia de celulas t modificadas de cd8. |
DE102020111571A1 (de) * | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
EP4271481A2 (en) * | 2020-12-31 | 2023-11-08 | Immatics US, Inc. | Cd8 polypeptides, compositions, and methods of using thereof |
MX2023012902A (es) | 2021-05-05 | 2023-11-08 | Immatics Biotechnologies Gmbh | Proteinas de union a antigenos que se unen especificamente a prame. |
US20230190805A1 (en) * | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Methods of identifying metastatic lesions in a patient and treating thereof |
US20230192886A1 (en) * | 2021-11-08 | 2023-06-22 | Immatics Biotechnologies Gmbh | Adoptive cell therapy combination treatment and compositions thereof |
WO2023148494A1 (en) * | 2022-02-03 | 2023-08-10 | University College Cardiff Consultants Limited | Novel t-cell receptor |
US20230348561A1 (en) * | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
CN117777314B (zh) * | 2024-02-26 | 2024-05-14 | 赛德特生物制药有限公司 | 慢病毒载体及其应用 |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5612114B2 (es) | 1974-06-07 | 1981-03-18 | ||
US4231938A (en) | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
US4444784A (en) | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
MX7065E (es) | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
US4450171A (en) | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
US4448784A (en) | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
US4739073A (en) | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US4915954A (en) | 1987-09-03 | 1990-04-10 | Alza Corporation | Dosage form for delivering a drug at two different rates |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5316765A (en) | 1989-09-07 | 1994-05-31 | Karl Folkers Foundation For Biomedical And Clinical Research | Use of coenzyme Q10 in combination with HMG-CoA reductase inhibitor therapies |
JPH07505773A (ja) | 1992-04-03 | 1995-06-29 | ヤング アレキサンダー ティー | 標的化されたウイルスベクターを用いた遺伝子治療 |
DE4309553A1 (de) | 1993-03-24 | 1994-09-29 | Bayer Ag | Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat |
AU682253B2 (en) | 1994-01-28 | 1997-09-25 | Immunex Corporation | CD 69 transcriptional regulatory elements |
US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
GB0028429D0 (en) | 2000-11-22 | 2001-01-10 | Astrazeneca Ab | Therapy |
GB0114533D0 (en) | 2001-06-14 | 2001-08-08 | Avidex Ltd | Substances |
GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
JP2007524591A (ja) | 2003-03-19 | 2007-08-30 | アイソジェニス・インコーポレイテッド | 同種拒絶反応の特異的阻害 |
WO2010042490A1 (en) * | 2008-10-06 | 2010-04-15 | Boston Medical Center Corporation | A single lentiviral vector system for induced pluripotent (ips) stem cells derivation |
AU2010225456B2 (en) | 2009-03-18 | 2016-03-17 | Carina Biotech Pty Ltd | Biomarkers and uses thereof |
US9840695B2 (en) | 2009-04-28 | 2017-12-12 | Agriculture Victoria Services Pty Ltd | Plant technology |
GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
ES2754394T3 (es) | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Receptores de antígenos quiméricos con una región bisagra optimizada |
WO2014090985A1 (en) | 2012-12-13 | 2014-06-19 | Universität Leipzig | T-cell modulation by exon skipping |
ES2928000T3 (es) | 2014-06-06 | 2022-11-14 | Memorial Sloan Kettering Cancer Center | Receptores de antígeno quimérico dirigidos a mesotelina y usos de los mismos |
US10975137B2 (en) | 2014-11-06 | 2021-04-13 | University Of Maryland, Baltimore | CD8a and t cell receptor variants and methods of using same in modulating immune cell responses |
GB201423361D0 (en) | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
GB201510771D0 (en) | 2015-06-19 | 2015-08-05 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy and methods for generating scaffolds for the use against pancreatic cancer |
GB201511191D0 (en) | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
GB201511792D0 (en) | 2015-07-06 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers |
GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
US20170136108A1 (en) | 2015-08-28 | 2017-05-18 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
AU2016323069A1 (en) | 2015-09-14 | 2018-04-12 | Alpine Immune Sciences, Inc. | Tunable variant immunoglobulin superfamily domains and engineered cell therapy |
GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
WO2017060201A1 (en) | 2015-10-09 | 2017-04-13 | Immatics Biotechnologies Gmbh | Anti-wt1/hla-specific antibodies |
AU2016366226B2 (en) | 2015-12-09 | 2023-06-01 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of using same |
GB201521746D0 (en) | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
GB201521894D0 (en) | 2015-12-11 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various cancers |
GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
EP3909978A1 (en) | 2016-02-05 | 2021-11-17 | Orionis Biosciences BV | Clec9a binding agents and use thereof |
GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
GB201603568D0 (en) | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
DK3430030T3 (da) | 2016-03-16 | 2024-01-22 | Immatics Biotechnologies Gmbh | Transficerede t-celler og t-cellereceptorer til anvendelse i immunoterapi mod cancer |
GB201604492D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers |
GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
GB201604494D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
CA3032838A1 (en) | 2016-08-04 | 2018-02-08 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
DE102016115246C5 (de) | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
ZA201900664B (en) | 2016-08-17 | 2021-09-29 | Paul Ehrlich Strasse 15 Tuebingen 72076 Germany | T cell receptors and immune therapy using the same |
EP3516044A4 (en) | 2016-09-23 | 2020-03-11 | Fred Hutchinson Cancer Research Center | SPECIFIC TCRs OF THE MINOR HISTOCOMPATIBILITY (H) ANTIGEN HA-1 AND USES THEREOF |
EP3300863B1 (en) | 2016-09-28 | 2020-06-17 | Braun GmbH | Electric shaver |
EP4032544A3 (en) | 2016-12-08 | 2022-12-21 | Immatics Biotechnologies GmbH | Novel t cell receptors and immune therapy using the same |
DE102016123847B3 (de) | 2016-12-08 | 2018-04-05 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
DE102016123859B3 (de) | 2016-12-08 | 2018-03-01 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
EP3579877A4 (en) | 2017-02-09 | 2020-12-09 | The Regents of The University of California | CHEMERIC T-LYMPHOCYTE ANTIGENIC RECEPTORS AND METHODS OF USE |
DE102017106305A1 (de) | 2017-03-23 | 2018-09-27 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
US11236145B2 (en) | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
US11427614B2 (en) | 2017-04-10 | 2022-08-30 | Immatics Biotechnologies Gmbh | Peptides and combination thereof for use in the immunotherapy against cancers |
EA201992416A1 (ru) | 2017-04-10 | 2020-02-25 | Имматикс Байотекнолоджиз Гмбх | Пептиды и комбинации пептидов для применения в иммунотерапии лейкозов и других видов рака |
US11235004B2 (en) | 2017-06-30 | 2022-02-01 | Innovative Cellular Therapeutics Holdings, Ltd. | Lymphocyte cell lines and uses thereof |
DE102017114737A1 (de) | 2017-06-30 | 2019-01-03 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie |
ES2871146T3 (es) | 2017-07-14 | 2021-10-28 | Immatics Biotechnologies Gmbh | Molécula de polipéptido con especificidad dual mejorada |
BR112020006643A2 (pt) | 2017-10-03 | 2020-09-24 | Juno Therapeutics Inc | moléculas de ligação específica ao hpv |
US11008556B2 (en) | 2017-10-12 | 2021-05-18 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor (CAR) and T cell receptor (TCR) modified T cells |
IL308007A (en) | 2017-11-06 | 2023-12-01 | Immatics Biotechnologies Gmbh | Transgenic T-cell receptors and immunotherapy using them |
MA51792A (fr) | 2018-02-09 | 2020-12-16 | Immatics Us Inc | Procédés de fabrication de lymphocytes t |
DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
DE102018108612A1 (de) | 2018-03-21 | 2019-09-26 | Immatics US, Inc. | Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen |
KR20210003826A (ko) * | 2018-04-19 | 2021-01-12 | 베이롤 칼리지 오브 메드신 | CD8αβ 및 클래스 1 제한된 T 세포 수용체의 강제 발현에 의한 CD4 T 세포의 세포독성 CD8 세포로의 재프로그래밍 |
CN113166778A (zh) | 2018-09-05 | 2021-07-23 | 葛兰素史克知识产权开发有限公司 | T细胞修饰 |
-
2020
- 2020-05-27 WO PCT/US2020/034639 patent/WO2020243134A1/en unknown
- 2020-05-27 CR CR20210669A patent/CR20210669A/es unknown
- 2020-05-27 BR BR112021023782A patent/BR112021023782A2/pt unknown
- 2020-05-27 AU AU2020283500A patent/AU2020283500A1/en active Pending
- 2020-05-27 CN CN202080039116.XA patent/CN113874516A/zh active Pending
- 2020-05-27 EA EA202193139A patent/EA202193139A1/ru unknown
- 2020-05-27 US US16/884,804 patent/US11975025B2/en active Active
- 2020-05-27 PE PE2021001957A patent/PE20220164A1/es unknown
- 2020-05-27 SG SG11202112860PA patent/SG11202112860PA/en unknown
- 2020-05-27 CA CA3141505A patent/CA3141505A1/en active Pending
- 2020-05-27 MA MA056036A patent/MA56036A/fr unknown
- 2020-05-27 EP EP20733114.1A patent/EP3976805A1/en active Pending
- 2020-05-27 KR KR1020217042442A patent/KR20220029584A/ko unknown
- 2020-05-27 JP JP2021570189A patent/JP2022534716A/ja active Pending
- 2020-05-27 MX MX2021014552A patent/MX2021014552A/es unknown
- 2020-05-27 TW TW109117632A patent/TW202110875A/zh unknown
-
2021
- 2021-11-25 IL IL288403A patent/IL288403A/en unknown
- 2021-11-26 CL CL2021003146A patent/CL2021003146A1/es unknown
- 2021-12-22 CO CONC2021/0017650A patent/CO2021017650A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021023782A2 (pt) | 2022-01-11 |
AU2020283500A1 (en) | 2022-01-27 |
CA3141505A1 (en) | 2020-12-03 |
CN113874516A (zh) | 2021-12-31 |
CO2021017650A2 (es) | 2022-04-19 |
PE20220164A1 (es) | 2022-01-28 |
CL2021003146A1 (es) | 2022-09-09 |
EA202193139A1 (ru) | 2022-03-01 |
TW202110875A (zh) | 2021-03-16 |
WO2020243134A1 (en) | 2020-12-03 |
MX2021014552A (es) | 2022-02-11 |
SG11202112860PA (en) | 2021-12-30 |
US11975025B2 (en) | 2024-05-07 |
IL288403A (en) | 2022-01-01 |
JP2022534716A (ja) | 2022-08-03 |
US20200376031A1 (en) | 2020-12-03 |
MA56036A (fr) | 2022-04-06 |
EP3976805A1 (en) | 2022-04-06 |
KR20220029584A (ko) | 2022-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021014552A (es) | Vectores viricos y uso de los mismos en terapias celulares adoptivas. | |
PH12018502645A1 (en) | Optimized mini-dystrophin genes and expression cassettes and their use | |
MX2021006646A (es) | Vector viral adenoasociado recombinante para el suministro de genes. | |
MX2022006427A (es) | "construcciones para terapia génica con microdistrofina y uso de las mismas. | |
MX2022006188A (es) | Variantes del vector viral adenoasociado. | |
PH12018502047A1 (en) | Neoantigens and methods of their use | |
PH12020551818A1 (en) | Gene therapy constructs and methods of use | |
MX2017010553A (es) | Vector. | |
MX2018010842A (es) | Expresion mediada por el virus adeno-asociado (aav) usando un promotor y pontenciador sintetico. | |
MX2021011997A (es) | Enlazadores de conjugacion mejorados. | |
MY169703A (en) | Antimicrobial fusion compounds and uses thereof | |
SG11201804006QA (en) | Novel peptide | |
MX2021007221A (es) | Factor i del complemento y cofactor del factor i del complemento, vectores que realizan codificacion para estos y uso terapeutico. | |
MX2021005656A (es) | Seleccion de mutaciones de cancer para la generacion de una vacuna contra cancer personalizada. | |
NZ801728A (en) | Atf5 peptide variants and uses thereof | |
PH12017500047A1 (en) | Dual cistronic bacterial expression system | |
EP3996744A4 (en) | VIRAL VECTOR THERAPY | |
MX2021002041A (es) | Terapia génica para el tratamiento de galactosemia. | |
MX2022011077A (es) | Variantes de transglutaminasa. | |
MX2019004183A (es) | Secuencia de nucleotidos que expresa una proteina de anclaje a exosoma para su uso como vacuna. | |
MX2018010061A (es) | Preparaciones de vectores retrovirales de genomas multiples, y metodos y sistemas para producir y usar las mismas. | |
MX2020001655A (es) | Vacuna vph. | |
WO2018183692A8 (en) | VECTORS AND COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | |
MX2021015766A (es) | Nuevos antigenos y metodos contra el cancer. | |
MX2018013205A (es) | Ensayo de potencia relativa para un vector viral que codifica isomero hidrolasas. |